• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Slides for the September 16, 2010 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee

 

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance
 
 
FDA
 
FDA Core Presentations, LORQESS (lorcaserin hydrochloride), for the September 16, 2010 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee
 
 
Todd Bourcier, Ph.D., Supervisory Pharmacologist, Division of Metabolism and Endocrinology Products (DMEP), Office of Drug Evaluation (ODE) II, Office of New Drugs (OND), CDER, FDA (PDF – 299KB)
 
Fred K. Alavi, Ph.D., Pharmacology/Toxicology Reviewer, DMEP, ODE II, OND CDER, FDA (PDF – 506KB)
 
Julie K. Golden, M.D., Clinical Reviewer, DMEP, ODE II, OND, CDER, FDA (PDF – 635KB)
 
 
 
Sponsor
 
 
Arena Pharmaceuticals, Inc., Core Presentations,LORQESS (lorcaserin hydrochloride), for the September 16, 2010 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (PDF - 3.68MB)
 
Arena Pharmaceuticals, Inc., Backup Presentation Slides (PDF – 828KB)
 
 
 
Open Public Hearing Slide Presentations
 
 
George Bray, M.D., The Obesity Society (PDF – 58KB)
 
Morgan Downey, J.D., Publisher & Editor, The Downey Obesity Report (PDF – 328KB)
 
Domenica Rubino, M.D., Director, Washington Center for Weight Management and Research (PDF – 275KB)
 
Denise Bruner, M.D., FASBP, American Society of Bariatric Physicians (PDF – 120KB)